Literature DB >> 18333222

Surgical therapy for testicular cancer metastatic to the liver.

Mary Maluccio1, Lawrence H Einhorn, Robert J Goulet.   

Abstract

In recent years improved cure rates have been achieved for testicular cancer. A better understanding of the biology of subtypes of testicular cancer and the introduction of surgical intervention has contributed greatly to how we currently approach a young man with testicular cancer. We describe here experience at our institution of the treatment, results and prognostic factors for testicular cancer metastases to the liver. Careful diagnostic work-up and planning of the therapy are required, in cooperation with an experienced team.

Entities:  

Year:  2007        PMID： 18333222      PMCID： PMC2063601          DOI： 10.1080/13651820500472101

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN： 1365-182X            Impact factor:   3.647


  13 in total

Review 1.  Hepatic colorectal metastasis: current surgical therapy, selection criteria for hepatectomy, and role for adjuvant therapy.

Authors:  Y Fong
Journal:  Adv Surg       Date:  2000

2.  Partial hepatectomy for metastases from noncolorectal, nonneuroendocrine carcinoma.

Authors:  Jürgen Weitz; Leslie H Blumgart; Yuman Fong; William R Jarnagin; Michael D'Angelica; Lawrence E Harrison; Ronald P DeMatteo
Journal:  Ann Surg       Date:  2005-02       Impact factor: 12.969

Review 3.  Surgical therapy of hepatic colorectal metastasis.

Authors:  Y Fong
Journal:  CA Cancer J Clin       Date:  1999 Jul-Aug       Impact factor: 508.702

4.  International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group.

Authors: 
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

5.  Curing metastatic testicular cancer.

Authors:  Lawrence H Einhorn
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-19       Impact factor: 11.205

6.  Hepatic resection for disseminated germ cell carcinoma.

Authors:  R J Goulet; J M Hardacre; L H Einhorn; P J Loehrer; J A Jones; J P Donohue; J A Madura; J L Grosfeld
Journal:  Ann Surg       Date:  1990-09       Impact factor: 12.969

7.  Liver metastases in germ cell cancer: defining a role for surgery after chemotherapy.

Authors:  Ellen Copson; Joe McKendrick; Niklas Hennessey; Ken Tung; Graham Z Mead
Journal:  BJU Int       Date:  2004-09       Impact factor: 5.588

8.  Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach.

Authors:  Dennis S Chi; Corinna C Franklin; Douglas A Levine; Faina Akselrod; Paul Sabbatini; William R Jarnagin; Ronald DeMatteo; Elizabeth A Poynor; Nadeem R Abu-Rustum; Richard R Barakat
Journal:  Gynecol Oncol       Date:  2004-09       Impact factor: 5.482

9.  Surgical resection in patients with nonseminomatous germ cell tumor who fail to normalize serum tumor markers after chemotherapy.

Authors:  J A Eastham; T G Wilson; C Russell; T E Ahlering; D G Skinner
Journal:  Urology       Date:  1994-01       Impact factor: 2.649

Review 10.  Surgery in metastatic testicular cancer.

Authors:  Peter Albers; Diethild Melchior; Stefan C Müller
Journal:  Eur Urol       Date:  2003-08       Impact factor: 20.096
View more
  2 in total

1.  Liver Resection for Non-colorectal Non-neuroendocrine Metastases: Where Do We Stand Today Compared to Colorectal Cancer?

Authors:  Tobias S Schiergens; Juliane Lüning; Bernhard W Renz; Michael Thomas; Sebastian Pratschke; Hao Feng; Serene M L Lee; Jutta Engel; Markus Rentsch; Markus Guba; Jens Werner; Wolfgang E Thasler
Journal:  J Gastrointest Surg       Date:  2016-02-26       Impact factor: 3.452

Review 2.  The benefits of liver resection for non-colorectal, non-neuroendocrine liver metastases: a systematic review.

Authors:  Timothy L Fitzgerald; Jason Brinkley; Shannon Banks; Nasreen Vohra; Zachary P Englert; Emmanuel E Zervos
Journal:  Langenbecks Arch Surg       Date:  2014-08-23       Impact factor: 3.445
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.